KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.79
+0.02 (0.07%)
May 22, 2026, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 275 employees as of December 31, 2025. The number of employees increased by 5 or 1.85% since the number was reported on April 30, 2025.
Employees
275
Change
5
Growth
1.85%
Revenue / Employee
$416,291
Profits / Employee
-$494,316
Market Cap
1.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 275 | - | - |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Ardelyx | 489 |
| UroGen Pharma | 298 |
| Biohaven | 274 |
| Precigen | 160 |
| Maze Therapeutics | 141 |
| Inhibrx Biosciences | 110 |
KALV News
- 11 days ago - KalVista Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 18 days ago - KalVista downgraded to Hold from Buy at Stifel - TheFly
- 24 days ago - KalVista downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 25 days ago - KalVista downgraded to Hold from Buy at Needham - TheFly
- 25 days ago - KalVista downgraded to Hold from Buy at JonesResearch - TheFly
- 26 days ago - KalVista downgraded to Market Perform from Outperform at Leerink - TheFly
- 26 days ago - KalVista downgraded to Market Perform from Outperform at Citizens - TheFly
- 26 days ago - KalVista moved to No Rating at BofA - TheFly